BIOMARKER:

ALK rearrangement

News alerts, weekly reports and conference planners

Entrez ID:

238

Related biomarkers:

‹

›

ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : A2 ESMO 2022 - 3wk	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks alectinib Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : C3 ESMO 2022 - 3wk	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks alectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks (New C4) crizotinib Resistant : C4 Exp Ther Med - 3wk	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks crizotinib Resistant : C4 Exp Ther Med - 3 weeks - (New C4)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
ALK rearrangement	Solid Tumor	ALK rearrangement	Solid Tumor	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ALK rearrangement	Non-Hodgkin’s Lymphoma	ALK rearrangement	Non-Hodgkin’s Lymphoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
ALK rearrangement	Lung Non-Small Cell Squamous Cancer	ALK rearrangement	Lung Non-Small Cell Squamous Cancer	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	WX-0593 Sensitive: C3 – Early Trials WX-0593 Sensitive : C3	WX-0593 Sensitive: C3 – Early Trials WX-0593 Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
ALK rearrangement	Renal Cell Carcinoma	ALK rearrangement	Renal Cell Carcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK rearrangement	Sarcoma	ALK rearrangement	Sarcoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	bevacizumab Sensitive: C4 – Case Studies bevacizumab Sensitive : C4	bevacizumab Sensitive: C4 – Case Studies bevacizumab Sensitive : C4
ALK rearrangement	Renal Cell Carcinoma	ALK rearrangement	Renal Cell Carcinoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	BMS-722782 Sensitive: D – Preclinical BMS-722782 Sensitive : D	BMS-722782 Sensitive: D – Preclinical BMS-722782 Sensitive : D
ALK rearrangement	Small Cell Lung Cancer	ALK rearrangement	Small Cell Lung Cancer	alectinib Sensitive: D – Preclinical alectinib Sensitive : D	alectinib Sensitive: D – Preclinical alectinib Sensitive : D
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	alectinib + YHO-1701 Sensitive: D – Preclinical alectinib + YHO-1701 Sensitive : D	alectinib + YHO-1701 Sensitive: D – Preclinical alectinib + YHO-1701 Sensitive : D

ALK rearrangement

Associations